WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a ...

Beigene Switzerland GmbH has divulged CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Polo-like kinase 1 (PLK1) is a conserved ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Continue advancement of MRT-6160 through Phase 2 initiation, in collaboration with Novartis. Share additional MRT-2359 Phase 1/2 study data in ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for treating adults with advanced or metastatic solid tumours. The dose ...

In this article, García-Vázquez et al. report valuable findings demonstrating that G2 and S phases expressed protein 1 (GTSE1), is a previously unappreciated non-pocket substrate of the cyclin ...